Voyager Acquisition Corp.
VACHU
NASDAQ14.50
USD
+1.00
- -
CIK
0002006815
ISIN
KYG93A7H1207
CUSIP
91854V206
Return %
Stock
S&P500
1Y
26.09
15.98
3Y
45.00
62.25
5Y
45.00
67.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Adeel Rouf
- Full Time Employees
- 3
- Sector
- Financial Services
- Industry
- Financial - Conglomerates
- Address
- 131 Concord Street Brooklyn NY United States of America 11201
- IPO Date
- Aug 9, 2024
- CIK
- 0002006815
- Website
- voyageracq.com
- Similar Companies
- Business
- Voyager Acquisition Corp is a special purpose acquisition company (SPAC) focused on acquiring and merging with businesses in the healthcare and healthcare-related industries. Founded in 2023 and headquartered in Brooklyn, New York, the company does not conduct operations of its own but raises capital through an initial public offering to effect mergers, capital stock exchanges, asset acquisitions, stock purchases, reorganizations, or similar business combinations. Voyager Acquisition Corp's core services include executing de-SPAC transactions, conducting due diligence, financial structuring, merger negotiations, and post-merger integration planning primarily within the healthcare sector. Its units trade on NASDAQ under the ticker symbol VACHU. A recent major development includes Voyager Acquisition Corp's definitive business combination agreement signed in April 2025 with VERAXA Biotech AG, a clinical-stage biopharmaceutical company developing next-generation cancer therapies. This transaction, structured as a two-step merger involving a Swiss public limited holding company and a Cayman Islands merger subsidiary, aims to transform Voyager from a blank-check company into an operating biopharmaceutical group with an expanded pipeline and Nasdaq listing under the proposed ticker VERX. Additionally, the merger deadline was extended to August 2026, and certain SPAC termination fee obligations were removed to facilitate completion of the transaction. These activities reflect Voyager's strategic expansion from capital raising to direct healthcare industry operations via acquisition and integration, focusing on advanced biomedical innovations and oncology.
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies
Voyager Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about September 30, 2024